Report Overview
HER2, also known as human epidermal growth factor receptor 2, is an important prognostic factor for breast cancer.HER2 is also expressed on the surface of some normal cells in the body.Her2-positive breast cancer is characterized by strong invasion, more recurrence and metastasis, and short disease-free survival.
This report provides a deep insight into the global HER2-Positive Breast Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global HER2-Positive Breast Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HER2-Positive Breast Cancer market in any manner.
Global HER2-Positive Breast Cancer Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Pfizer (Pharmacia and Upjohn Company)
Novartis
AstraZeneca Pharmaceuticals
Eli Lilly
Roche Group
Merck
Jiangsu HengRui Medicine
Odonate Therapeutics
Radius Pharmaceuticals
Immunomedics
Syndax Pharmaceuticals
Bayer
Eagle Pharmaceuticals
Merrimack Pharmaceuticals
GlaxoSmithKline
Millennium Pharmaceuticals
Market Segmentation (by Type)
Grifola Frondosa
Surgery
Radiation and Chemotherapy
Endocrine Therapy
Molecular Targeted Therapy
Market Segmentation (by Application)
Hospital
Specialist Clinic
Biotechnology and Pharmaceutical Companies
Research and Academic Institutions
Other
Geographic Segmentation
? North America (USA, Canada, Mexico)
? Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
? Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
? South America (Brazil, Argentina, Columbia, Rest of South America)
? The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
? Industry drivers, restraints, and opportunities covered in the study
? Neutral perspective on the market performance
? Recent industry trends and developments
? Competitive landscape & strategies of key players
? Potential & niche segments and regions exhibiting promising growth covered
? Historical, current, and projected market size, in terms of value
? In-depth analysis of the HER2-Positive Breast Cancer Market
? Overview of the regional outlook of the HER2-Positive Breast Cancer Market:
Key Reasons to Buy this Report:
? Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
? This enables you to anticipate market changes to remain ahead of your competitors
? You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
? The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
? Provision of market value (USD Billion) data for each segment and sub-segment
? Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
? Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
? Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
? Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
? The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
? Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
? Provides insight into the market through Value Chain
? Market dynamics scenario, along with growth opportunities of the market in the years to come
? 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the HER2-Positive Breast Cancer Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of HER2-Positive Breast Cancer
1.2 Key Market Segments
1.2.1 HER2-Positive Breast Cancer Segment by Type
1.2.2 HER2-Positive Breast Cancer Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 HER2-Positive Breast Cancer Market Overview
2.1 Global Market Overview
2.1.1 Global HER2-Positive Breast Cancer Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global HER2-Positive Breast Cancer Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 HER2-Positive Breast Cancer Market Competitive Landscape
3.1 Global HER2-Positive Breast Cancer Sales by Manufacturers (2019-2024)
3.2 Global HER2-Positive Breast Cancer Revenue Market Share by Manufacturers (2019-2024)
3.3 HER2-Positive Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global HER2-Positive Breast Cancer Average Price by Manufacturers (2019-2024)
3.5 Manufacturers HER2-Positive Breast Cancer Sales Sites, Area Served, Product Type
3.6 HER2-Positive Breast Cancer Market Competitive Situation and Trends
3.6.1 HER2-Positive Breast Cancer Market Concentration Rate
3.6.2 Global 5 and 10 Largest HER2-Positive Breast Cancer Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 HER2-Positive Breast Cancer Industry Chain Analysis
4.1 HER2-Positive Breast Cancer Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of HER2-Positive Breast Cancer Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 HER2-Positive Breast Cancer Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global HER2-Positive Breast Cancer Sales Market Share by Type (2019-2024)
6.3 Global HER2-Positive Breast Cancer Market Size Market Share by Type (2019-2024)
6.4 Global HER2-Positive Breast Cancer Price by Type (2019-2024)
7 HER2-Positive Breast Cancer Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global HER2-Positive Breast Cancer Market Sales by Application (2019-2024)
7.3 Global HER2-Positive Breast Cancer Market Size (M USD) by Application (2019-2024)
7.4 Global HER2-Positive Breast Cancer Sales Growth Rate by Application (2019-2024)
8 HER2-Positive Breast Cancer Market Segmentation by Region
8.1 Global HER2-Positive Breast Cancer Sales by Region
8.1.1 Global HER2-Positive Breast Cancer Sales by Region
8.1.2 Global HER2-Positive Breast Cancer Sales Market Share by Region
8.2 North America
8.2.1 North America HER2-Positive Breast Cancer Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe HER2-Positive Breast Cancer Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific HER2-Positive Breast Cancer Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America HER2-Positive Breast Cancer Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa HER2-Positive Breast Cancer Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Pfizer (Pharmacia and Upjohn Company)
9.1.1 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Basic Information
9.1.2 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product Overview
9.1.3 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product Market Performance
9.1.4 Pfizer (Pharmacia and Upjohn Company) Business Overview
9.1.5 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer SWOT Analysis
9.1.6 Pfizer (Pharmacia and Upjohn Company) Recent Developments
9.2 Novartis
9.2.1 Novartis HER2-Positive Breast Cancer Basic Information
9.2.2 Novartis HER2-Positive Breast Cancer Product Overview
9.2.3 Novartis HER2-Positive Breast Cancer Product Market Performance
9.2.4 Novartis Business Overview
9.2.5 Novartis HER2-Positive Breast Cancer SWOT Analysis
9.2.6 Novartis Recent Developments
9.3 AstraZeneca Pharmaceuticals
9.3.1 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.3.2 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.3.3 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.3.4 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer SWOT Analysis
9.3.5 AstraZeneca Pharmaceuticals Business Overview
9.3.6 AstraZeneca Pharmaceuticals Recent Developments
9.4 Eli Lilly
9.4.1 Eli Lilly HER2-Positive Breast Cancer Basic Information
9.4.2 Eli Lilly HER2-Positive Breast Cancer Product Overview
9.4.3 Eli Lilly HER2-Positive Breast Cancer Product Market Performance
9.4.4 Eli Lilly Business Overview
9.4.5 Eli Lilly Recent Developments
9.5 Roche Group
9.5.1 Roche Group HER2-Positive Breast Cancer Basic Information
9.5.2 Roche Group HER2-Positive Breast Cancer Product Overview
9.5.3 Roche Group HER2-Positive Breast Cancer Product Market Performance
9.5.4 Roche Group Business Overview
9.5.5 Roche Group Recent Developments
9.6 Merck
9.6.1 Merck HER2-Positive Breast Cancer Basic Information
9.6.2 Merck HER2-Positive Breast Cancer Product Overview
9.6.3 Merck HER2-Positive Breast Cancer Product Market Performance
9.6.4 Merck Business Overview
9.6.5 Merck Recent Developments
9.7 Jiangsu HengRui Medicine
9.7.1 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Basic Information
9.7.2 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product Overview
9.7.3 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product Market Performance
9.7.4 Jiangsu HengRui Medicine Business Overview
9.7.5 Jiangsu HengRui Medicine Recent Developments
9.8 Odonate Therapeutics
9.8.1 Odonate Therapeutics HER2-Positive Breast Cancer Basic Information
9.8.2 Odonate Therapeutics HER2-Positive Breast Cancer Product Overview
9.8.3 Odonate Therapeutics HER2-Positive Breast Cancer Product Market Performance
9.8.4 Odonate Therapeutics Business Overview
9.8.5 Odonate Therapeutics Recent Developments
9.9 Radius Pharmaceuticals
9.9.1 Radius Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.9.2 Radius Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.9.3 Radius Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.9.4 Radius Pharmaceuticals Business Overview
9.9.5 Radius Pharmaceuticals Recent Developments
9.10 Immunomedics
9.10.1 Immunomedics HER2-Positive Breast Cancer Basic Information
9.10.2 Immunomedics HER2-Positive Breast Cancer Product Overview
9.10.3 Immunomedics HER2-Positive Breast Cancer Product Market Performance
9.10.4 Immunomedics Business Overview
9.10.5 Immunomedics Recent Developments
9.11 Syndax Pharmaceuticals
9.11.1 Syndax Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.11.2 Syndax Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.11.3 Syndax Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.11.4 Syndax Pharmaceuticals Business Overview
9.11.5 Syndax Pharmaceuticals Recent Developments
9.12 Bayer
9.12.1 Bayer HER2-Positive Breast Cancer Basic Information
9.12.2 Bayer HER2-Positive Breast Cancer Product Overview
9.12.3 Bayer HER2-Positive Breast Cancer Product Market Performance
9.12.4 Bayer Business Overview
9.12.5 Bayer Recent Developments
9.13 Eagle Pharmaceuticals
9.13.1 Eagle Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.13.2 Eagle Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.13.3 Eagle Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.13.4 Eagle Pharmaceuticals Business Overview
9.13.5 Eagle Pharmaceuticals Recent Developments
9.14 Merrimack Pharmaceuticals
9.14.1 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.14.2 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.14.3 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.14.4 Merrimack Pharmaceuticals Business Overview
9.14.5 Merrimack Pharmaceuticals Recent Developments
9.15 GlaxoSmithKline
9.15.1 GlaxoSmithKline HER2-Positive Breast Cancer Basic Information
9.15.2 GlaxoSmithKline HER2-Positive Breast Cancer Product Overview
9.15.3 GlaxoSmithKline HER2-Positive Breast Cancer Product Market Performance
9.15.4 GlaxoSmithKline Business Overview
9.15.5 GlaxoSmithKline Recent Developments
9.16 Millennium Pharmaceuticals
9.16.1 Millennium Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.16.2 Millennium Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.16.3 Millennium Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.16.4 Millennium Pharmaceuticals Business Overview
9.16.5 Millennium Pharmaceuticals Recent Developments
10 HER2-Positive Breast Cancer Market Forecast by Region
10.1 Global HER2-Positive Breast Cancer Market Size Forecast
10.2 Global HER2-Positive Breast Cancer Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe HER2-Positive Breast Cancer Market Size Forecast by Country
10.2.3 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Region
10.2.4 South America HER2-Positive Breast Cancer Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of HER2-Positive Breast Cancer by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global HER2-Positive Breast Cancer Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of HER2-Positive Breast Cancer by Type (2025-2030)
11.1.2 Global HER2-Positive Breast Cancer Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of HER2-Positive Breast Cancer by Type (2025-2030)
11.2 Global HER2-Positive Breast Cancer Market Forecast by Application (2025-2030)
11.2.1 Global HER2-Positive Breast Cancer Sales (K Units) Forecast by Application
11.2.2 Global HER2-Positive Breast Cancer Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. HER2-Positive Breast Cancer Market Size Comparison by Region (M USD)
Table 5. Global HER2-Positive Breast Cancer Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global HER2-Positive Breast Cancer Sales Market Share by Manufacturers (2019-2024)
Table 7. Global HER2-Positive Breast Cancer Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global HER2-Positive Breast Cancer Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER2-Positive Breast Cancer as of 2022)
Table 10. Global Market HER2-Positive Breast Cancer Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers HER2-Positive Breast Cancer Sales Sites and Area Served
Table 12. Manufacturers HER2-Positive Breast Cancer Product Type
Table 13. Global HER2-Positive Breast Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of HER2-Positive Breast Cancer
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. HER2-Positive Breast Cancer Market Challenges
Table 22. Global HER2-Positive Breast Cancer Sales by Type (K Units)
Table 23. Global HER2-Positive Breast Cancer Market Size by Type (M USD)
Table 24. Global HER2-Positive Breast Cancer Sales (K Units) by Type (2019-2024)
Table 25. Global HER2-Positive Breast Cancer Sales Market Share by Type (2019-2024)
Table 26. Global HER2-Positive Breast Cancer Market Size (M USD) by Type (2019-2024)
Table 27. Global HER2-Positive Breast Cancer Market Size Share by Type (2019-2024)
Table 28. Global HER2-Positive Breast Cancer Price (USD/Unit) by Type (2019-2024)
Table 29. Global HER2-Positive Breast Cancer Sales (K Units) by Application
Table 30. Global HER2-Positive Breast Cancer Market Size by Application
Table 31. Global HER2-Positive Breast Cancer Sales by Application (2019-2024) & (K Units)
Table 32. Global HER2-Positive Breast Cancer Sales Market Share by Application (2019-2024)
Table 33. Global HER2-Positive Breast Cancer Sales by Application (2019-2024) & (M USD)
Table 34. Global HER2-Positive Breast Cancer Market Share by Application (2019-2024)
Table 35. Global HER2-Positive Breast Cancer Sales Growth Rate by Application (2019-2024)
Table 36. Global HER2-Positive Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 37. Global HER2-Positive Breast Cancer Sales Market Share by Region (2019-2024)
Table 38. North America HER2-Positive Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 39. Europe HER2-Positive Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific HER2-Positive Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 41. South America HER2-Positive Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa HER2-Positive Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 43. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Basic Information
Table 44. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product Overview
Table 45. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Pfizer (Pharmacia and Upjohn Company) Business Overview
Table 47. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer SWOT Analysis
Table 48. Pfizer (Pharmacia and Upjohn Company) Recent Developments
Table 49. Novartis HER2-Positive Breast Cancer Basic Information
Table 50. Novartis HER2-Positive Breast Cancer Product Overview
Table 51. Novartis HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Novartis Business Overview
Table 53. Novartis HER2-Positive Breast Cancer SWOT Analysis
Table 54. Novartis Recent Developments
Table 55. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Basic Information
Table 56. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product Overview
Table 57. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer SWOT Analysis
Table 59. AstraZeneca Pharmaceuticals Business Overview
Table 60. AstraZeneca Pharmaceuticals Recent Developments
Table 61. Eli Lilly HER2-Positive Breast Cancer Basic Information
Table 62. Eli Lilly HER2-Positive Breast Cancer Product Overview
Table 63. Eli Lilly HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Eli Lilly Business Overview
Table 65. Eli Lilly Recent Developments
Table 66. Roche Group HER2-Positive Breast Cancer Basic Information
Table 67. Roche Group HER2-Positive Breast Cancer Product Overview
Table 68. Roche Group HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Roche Group Business Overview
Table 70. Roche Group Recent Developments
Table 71. Merck HER2-Positive Breast Cancer Basic Information
Table 72. Merck HER2-Positive Breast Cancer Product Overview
Table 73. Merck HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Merck Business Overview
Table 75. Merck Recent Developments
Table 76. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Basic Information
Table 77. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product Overview
Table 78. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Jiangsu HengRui Medicine Business Overview
Table 80. Jiangsu HengRui Medicine Recent Developments
Table 81. Odonate Therapeutics HER2-Positive Breast Cancer Basic Information
Table 82. Odonate Therapeutics HER2-Positive Breast Cancer Product Overview
Table 83. Odonate Therapeutics HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Odonate Therapeutics Business Overview
Table 85. Odonate Therapeutics Recent Developments
Table 86. Radius Pharmaceuticals HER2-Positive Breast Cancer Basic Information
Table 87. Radius Pharmaceuticals HER2-Positive Breast Cancer Product Overview
Table 88. Radius Pharmaceuticals HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Radius Pharmaceuticals Business Overview
Table 90. Radius Pharmaceuticals Recent Developments
Table 91. Immunomedics HER2-Positive Breast Cancer Basic Information
Table 92. Immunomedics HER2-Positive Breast Cancer Product Overview
Table 93. Immunomedics HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Immunomedics Business Overview
Table 95. Immunomedics Recent Developments
Table 96. Syndax Pharmaceuticals HER2-Positive Breast Cancer Basic Information
Table 97. Syndax Pharmaceuticals HER2-Positive Breast Cancer Product Overview
Table 98. Syndax Pharmaceuticals HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Syndax Pharmaceuticals Business Overview
Table 100. Syndax Pharmaceuticals Recent Developments
Table 101. Bayer HER2-Positive Breast Cancer Basic Information
Table 102. Bayer HER2-Positive Breast Cancer Product Overview
Table 103. Bayer HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Bayer Business Overview
Table 105. Bayer Recent Developments
Table 106. Eagle Pharmaceuticals HER2-Positive Breast Cancer Basic Information
Table 107. Eagle Pharmaceuticals HER2-Positive Breast Cancer Product Overview
Table 108. Eagle Pharmaceuticals HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Eagle Pharmaceuticals Business Overview
Table 110. Eagle Pharmaceuticals Recent Developments
Table 111. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Basic Information
Table 112. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product Overview
Table 113. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Merrimack Pharmaceuticals Business Overview
Table 115. Merrimack Pharmaceuticals Recent Developments
Table 116. GlaxoSmithKline HER2-Positive Breast Cancer Basic Information
Table 117. GlaxoSmithKline HER2-Positive Breast Cancer Product Overview
Table 118. GlaxoSmithKline HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. GlaxoSmithKline Business Overview
Table 120. GlaxoSmithKline Recent Developments
Table 121. Millennium Pharmaceuticals HER2-Positive Breast Cancer Basic Information
Table 122. Millennium Pharmaceuticals HER2-Positive Breast Cancer Product Overview
Table 123. Millennium Pharmaceuticals HER2-Positive Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Millennium Pharmaceuticals Business Overview
Table 125. Millennium Pharmaceuticals Recent Developments
Table 126. Global HER2-Positive Breast Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 127. Global HER2-Positive Breast Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 128. North America HER2-Positive Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 129. North America HER2-Positive Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 130. Europe HER2-Positive Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 131. Europe HER2-Positive Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 132. Asia Pacific HER2-Positive Breast Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 133. Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 134. South America HER2-Positive Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 135. South America HER2-Positive Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 136. Middle East and Africa HER2-Positive Breast Cancer Consumption Forecast by Country (2025-2030) & (Units)
Table 137. Middle East and Africa HER2-Positive Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 138. Global HER2-Positive Breast Cancer Sales Forecast by Type (2025-2030) & (K Units)
Table 139. Global HER2-Positive Breast Cancer Market Size Forecast by Type (2025-2030) & (M USD)
Table 140. Global HER2-Positive Breast Cancer Price Forecast by Type (2025-2030) & (USD/Unit)
Table 141. Global HER2-Positive Breast Cancer Sales (K Units) Forecast by Application (2025-2030)
Table 142. Global HER2-Positive Breast Cancer Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of HER2-Positive Breast Cancer
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global HER2-Positive Breast Cancer Market Size (M USD), 2019-2030
Figure 5. Global HER2-Positive Breast Cancer Market Size (M USD) (2019-2030)
Figure 6. Global HER2-Positive Breast Cancer Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. HER2-Positive Breast Cancer Market Size by Country (M USD)
Figure 11. HER2-Positive Breast Cancer Sales Share by Manufacturers in 2023
Figure 12. Global HER2-Positive Breast Cancer Revenue Share by Manufacturers in 2023
Figure 13. HER2-Positive Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market HER2-Positive Breast Cancer Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by HER2-Positive Breast Cancer Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global HER2-Positive Breast Cancer Market Share by Type
Figure 18. Sales Market Share of HER2-Positive Breast Cancer by Type (2019-2024)
Figure 19. Sales Market Share of HER2-Positive Breast Cancer by Type in 2023
Figure 20. Market Size Share of HER2-Positive Breast Cancer by Type (2019-2024)
Figure 21. Market Size Market Share of HER2-Positive Breast Cancer by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global HER2-Positive Breast Cancer Market Share by Application
Figure 24. Global HER2-Positive Breast Cancer Sales Market Share by Application (2019-2024)
Figure 25. Global HER2-Positive Breast Cancer Sales Market Share by Application in 2023
Figure 26. Global HER2-Positive Breast Cancer Market Share by Application (2019-2024)
Figure 27. Global HER2-Positive Breast Cancer Market Share by Application in 2023
Figure 28. Global HER2-Positive Breast Cancer Sales Growth Rate by Application (2019-2024)
Figure 29. Global HER2-Positive Breast Cancer Sales Market Share by Region (2019-2024)
Figure 30. North America HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America HER2-Positive Breast Cancer Sales Market Share by Country in 2023
Figure 32. U.S. HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada HER2-Positive Breast Cancer Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico HER2-Positive Breast Cancer Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe HER2-Positive Breast Cancer Sales Market Share by Country in 2023
Figure 37. Germany HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific HER2-Positive Breast Cancer Sales and Growth Rate (K Units)
Figure 43. Asia Pacific HER2-Positive Breast Cancer Sales Market Share by Region in 2023
Figure 44. China HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America HER2-Positive Breast Cancer Sales and Growth Rate (K Units)
Figure 50. South America HER2-Positive Breast Cancer Sales Market Share by Country in 2023
Figure 51. Brazil HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa HER2-Positive Breast Cancer Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa HER2-Positive Breast Cancer Sales Market Share by Region in 2023
Figure 56. Saudi Arabia HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa HER2-Positive Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global HER2-Positive Breast Cancer Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global HER2-Positive Breast Cancer Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global HER2-Positive Breast Cancer Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global HER2-Positive Breast Cancer Market Share Forecast by Type (2025-2030)
Figure 65. Global HER2-Positive Breast Cancer Sales Forecast by Application (2025-2030)
Figure 66. Global HER2-Positive Breast Cancer Market Share Forecast by Application (2025-2030)
